Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.

Szczegóły
Abstrakt

Tytuł:: Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.
Autorzy:: Pettengell R; Institute of Medical & Biomedical Education, St George's University of London, London, United Kingdom. .
Uddin R; EBMT Clinical Trials Office, European Society for Blood and Marrow Transplantation, London, United Kingdom.
Boumendil A; Statistics, European Society for Blood and Marrow Transplantation, Paris, France.
Johnson R; Department of Haematology, St James's University Hospital, Leeds, United Kingdom.
Metzner B; University Clinic for Internal Medicine, Oncology and Haematology, Klinikum Oldenburg, Oldenburg, Germany.
Martín A; Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.
Romejko-Jarosinska J; Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw, Poland.
Bence-Bruckler I; The University of Ottawa, The Ottawa Hospital, Ottawa, Canada.
Giri P; Haematology, Royal Adelaide Hospital, Adelaide, Southern Australia, Australia.
Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Robinson SP; Department of Haematology, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.
Kimby E; Department of Hematology, Karolinska Institute, Stockholm, Sweden.
Schmitz N; Department of Internal Medicine A, University Hospital Muenster, Muenster, Germany.
Dreger P; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Goldstone AH; University College London Hospital, London, United Kingdom.
Montoto S; Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.
Źródło:: Bone marrow transplantation [Bone Marrow Transplant] 2021 Jun; Vol. 56 (6), pp. 1413-1421. Date of Electronic Publication: 2021 Jan 15.
Typ publikacji:: Journal Article; Randomized Controlled Trial
Język:: English
Imprint Name(s):: Publication: <2003->: London : Nature Publishing Group
Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986-
MeSH Terms:: Hematopoietic Stem Cell Transplantation*
Lymphoma, Follicular*/drug therapy
Antineoplastic Combined Chemotherapy Protocols ; Autografts ; Combined Modality Therapy ; Follow-Up Studies ; Humans ; Neoplasm Recurrence, Local ; Prospective Studies ; Retrospective Studies ; Rituximab/therapeutic use ; Transplantation, Autologous
References:: Alperovich A, Batlevi C, Smith K, Ying Z, Soumerai JD, Copeland AR, et al. Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era. Blood. 2016;128:2955. (PMID: 10.1182/blood.V128.22.2955.2955)
Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: an analysis from the National LymphoCare study. J Clin Oncol. 2015;33:2516–22. (PMID: 10.1200/JCO.2014.59.7534)
Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, et al. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: a Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant. 2018;24:1172–9. (PMID: 10.1016/j.bbmt.2018.03.022)
Al Khabori M, de Almeida JR, Guyatt GH, Kuruvilla J, Crump M. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104:18–28. (PMID: 10.1093/jnci/djr450)
Oh DH, Li H, Duan Q, Villa D, Peters A, Chua N, et al. Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. Biol Blood Marrow Transplant. 2016;22:941–8. (PMID: 10.1016/j.bbmt.2016.01.015)
Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918–27. (PMID: 10.1200/JCO.2003.10.023)
Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica. 2011;96:1128–35. (PMID: 10.3324/haematol.2010.030320)
El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, et al. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Ann Oncol. 2014;25:2224–9. (PMID: 10.1093/annonc/mdu440)
Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, Hensel M, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009;20:722–8. (PMID: 10.1093/annonc/mdn691)
Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe. Bone Marrow Transplant. 2019;54:1525–52. (PMID: 10.1038/s41409-019-0516-2)
Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103:1799–806. (PMID: 10.1093/jnci/djr418)
Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, et al. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. Eur J Cancer. 2017;76:216–25. (PMID: 10.1016/j.ejca.2017.01.021)
van Oers MHJ, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853–8. (PMID: 10.1200/JCO.2009.26.5827)
Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624–30. (PMID: 10.1200/JCO.2012.47.1862)
Buyse M, Sargent DJ, Saad ED. Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol. 2011;29:4719–20. (PMID: 10.1200/JCO.2011.38.4206)
Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, et al. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: an Individual Patient-Level Analysis of Multiple Randomized Trials. J Clin Oncol. 2017;35:552–60. (PMID: 10.1200/JCO.2016.70.8651)
Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:3019.
NCCNGuidelines; https://www.nccn.org/professionals/physician_gls/default.aspx.
Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166–75. (PMID: 10.1200/JCO.2007.14.4204)
Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study. J Clin Oncol. 2019;37:2815–24. (PMID: 10.1200/JCO.19.01073)
Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, et al. Long-term follow-up of high dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21:2324–31. (PMID: 10.1038/sj.leu.2404850)
Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633–9. (PMID: 10.1182/blood.V87.9.3633.bloodjournal8793633)
Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2016;27:390–7. (PMID: 10.1093/annonc/mdv616)
Cheung KJ, Shah SP, Steidl C, Johnson N, Relander T, Telenius A, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009;113:137–48. (PMID: 10.1182/blood-2008-02-140616)
Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128:1112–20. (PMID: 10.1182/blood-2016-05-717355)
Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, et al. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32:1347–55. (PMID: 10.1200/JCO.2013.52.8190)
van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–301. (PMID: 10.1182/blood-2006-05-021113)
Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahe B, et al. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience. Ann Hematol. 2016;95:1287–93. (PMID: 10.1007/s00277-016-2705-z)
Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance Therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.CIBMTR and LWP-EBMT. J Am Med Assoc Oncol. 2019;5:715–22.
Zhang L, Ghielmini M, Cheson BD, Ujjani C. Pros and Cons of rituximab maintenance in follicular lymphoma. Cancer Treat Rev. 2017;58:34–40. (PMID: 10.1016/j.ctrv.2017.05.007)
Rashidi A, Oak E, Bartlett NL. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. Blood. 2015;125:3354–5. (PMID: 10.1182/blood-2015-02-628362)
Substance Nomenclature:: 4F4X42SYQ6 (Rituximab)
Entry Date(s):: Date Created: 20210116 Date Completed: 20210630 Latest Revision: 20210731
Update Code:: 20240105
DOI:: 10.1038/s41409-020-01182-w
PMID:: 33452448
: Czasopismo naukowe

We report the 12-year follow-up of the prospective randomized EBMT LYM1 trial to determine whether the benefit of brief duration rituximab maintenance (RM) on progression-free survival (PFS) in patients with relapsed follicular lymphoma (FL) receiving an autologous stem cell transplant (ASCT) is sustained. One hundred and thirty-eight patients received RM with or without purging. The median follow-up after random assignment is 12 years (range 10-13) for the whole series. The 10-year PFS after ASCT is 47% (95% CI 40-54) with only 4 patients relapsing after 7.5 years. RM continues to significantly improve 10-year PFS after ASCT in comparison with NM [P = 0.002; HR 0.548 (95% CI 0.38-0.80)]. Ten-year non-relapse mortality (NRM) was not significantly different between treatment groups (7% overall). 10-year overall survival (OS) after ASCT was 75% (69-81) for the whole series, with no significant differences according to treatment sub-groups. 10-year OS for patients who progressed within 24 months (POD24T) was 60%, in comparison with 85% for patients without progression. Thus the benefit of rituximab maintenance after ASCT on relapse prevention is sustained at 12 years, suggesting that RM adds to ASCT-mediated disease eradication and may enhance the curative potential of ASCT.

Informacja